Delving into the Latest Updates on Stemcyte International Ltd. with Synapse

概览

疾病领域	数量

感染	1
神经系统疾病	1

排名前五的药物类型	数量

造血干细胞疗法	1

关联

1

项与 Stemcyte International Ltd. 相关的药物

HPC-Cord Blood (StemCyte)

靶点-

作用机制

细胞替代物

在研机构

StemCyte, Inc. [+1]

原研机构

StemCyte, Inc.

在研适应症

造血干细胞移植 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2024-11-20

2

项与 Stemcyte International Ltd. 相关的临床试验

NCT05682560

/ Active, not recruiting临床2期

A Randomized Controlled Phase IIa, Two-arm Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

RegeneCyte (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.

开始日期2023-05-04

申办/合作机构

Stemcyte International Ltd.

[+1]

NCT03979742

/ Terminated临床2期

A Randomized Controlled Phase II, Two-Arm Study of Umbilical Cord Blood Cell Transplant (MC001) Into Injured Spinal Cord Followed by the Locomotor Training for Patients with Chronic Complete Spinal Cord Injuries (SCI).

Umbilical cord blood mononuclear stem cells (UCBMSCs) transplant followed by the intensive locomotor training for up to 5±1 hours a day, 5±1 days a week, and for 3-6 months for treatment in patients with chronic, stable and complete spinal cord injury.

开始日期2022-02-22

申办/合作机构

Stemcyte International Ltd.

[+1]

100 项与 Stemcyte International Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Stemcyte International Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Stemcyte International Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Stemcyte International Ltd. 相关的转化医学

登录后查看更多信息